Search results summary
From Health Canada
Search criteria
- Status: Select all
- AIG: 0152713002
Search results
| Status | DIN | Company | Product | Class | PM See footnote1 | Schedule | # See footnote2 | A.I. name See footnote3 | Strength |
|---|---|---|---|---|---|---|---|---|---|
| Marketed | 02424770 | HOFFMANN-LA ROCHE LIMITED | ACTEMRA | Human | Yes | SCHEDULE D | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02424770 | HOFFMANN-LA ROCHE LIMITED | ACTEMRA | Human | Yes | PRESCRIPTION | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02483327 | HOFFMANN-LA ROCHE LIMITED | ACTEMRA | Human | Yes | PRESCRIPTION | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02483327 | HOFFMANN-LA ROCHE LIMITED | ACTEMRA | Human | Yes | SCHEDULE D | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02562057 | CELLTRION INC. | AVTOZMA | Human | Yes | PRESCRIPTION | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02562057 | CELLTRION INC. | AVTOZMA | Human | Yes | SCHEDULE D | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02562065 | CELLTRION INC. | AVTOZMA | Human | Yes | PRESCRIPTION | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02562065 | CELLTRION INC. | AVTOZMA | Human | Yes | SCHEDULE D | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02552485 | FRESENIUS KABI CANADA LTD | TYENNE | Human | Yes | SCHEDULE D | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02552485 | FRESENIUS KABI CANADA LTD | TYENNE | Human | Yes | PRESCRIPTION | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02552493 | FRESENIUS KABI CANADA LTD | TYENNE | Human | Yes | SCHEDULE D | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
| Marketed | 02552493 | FRESENIUS KABI CANADA LTD | TYENNE | Human | Yes | PRESCRIPTION | 1 | TOCILIZUMAB | 162 MG / 0.9 ML |
Application information
Related information
Contact us
Version 4.0.3